Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - torisel
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp4e8e0c5f72dbc27f3ff2eb4a522fe300
identifier: http://ema.europa.eu/identifier
/EU/1/07/424/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Torisel 30 mg concentrate and solvent for solution for infusion
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-4e8e0c5f72dbc27f3ff2eb4a522fe300
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/07/424/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - torisel
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Torisel contains the active substance temsirolimus.
Temsirolimus is a selective inhibitor of the enzyme mTOR (mammalian target of rapamycin) that blocks tumour cell growth and division.
Torisel is used to treat the following types of cancer in adults:
Do not use Torisel
Warnings and precautions
Talk to your doctor, pharmacist or nurse before receiving Torisel
Tell your doctor if you are taking blood thinning medicines or have any bleeding or bruising while you are on Torisel.
Talk to your doctor, pharmacist, nurse if you have any concern.
Children and adolescents
This medicine is not for children and adolescents below 18 years of age because advanced cancer of the kidney and mantle cell lymphoma are not relevant for these patients, and it did not work in other cancers.
Other medicines and Torisel
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Some medicines can interfere with the breakdown or metabolism of Torisel and therefore dose adjustment of Torisel may be required. In particular, you should inform your doctor or pharmacist if you are taking any of the following:
Torisel with food and drink
Grapefruit and grapefruit juice may increase blood concentrations of Torisel and should be avoided.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before receiving this medicine.
Torisel has not been studied in pregnant women, and it must not be used during pregnancy, unless clearly necessary.
Women of childbearing potential must avoid pregnancy by using an effective method of birth control during treatment with Torisel. Men with partners of childbearing potential should use medically acceptable contraception while receiving Torisel.
Women should not breast-feed during treatment with Torisel, as this medicine may interfere with the growth and development of the baby.
Torisel contains alcohol (ethanol). If you are pregnant or breast-feeding your baby, you should talk to your doctor or pharmacist before taking this medicine.
Torisel contains propylene glycol. If you are pregnant, do not take this medicine unless recommended by your doctor (see section Torisel contains propylene glycol"). Propylene glycol may pass into breast milk, if you are breast-feeding, do not take this medicine unless recommended by your doctor (see section Torisel contains propylene glycol").
Driving and using machines
Torisel is unlikely to influence the ability to drive and use machines. However, feeling or being sick (nausea and vomiting) and difficulty in falling or staying asleep are very common side effects. If you
feel sick (nausea and vomiting) or you have difficulty in falling or staying asleep, take special care when driving or using machines.
For patients receiving the higher dose of Torisel for the treatment of mantle cell lymphoma, the amount of alcohol in this medicine may impair your ability to drive or use machines (see section below Torisel contains ethanol [alcohol] ).
Torisel contains ethanol (alcohol)
This medicine contains ethanol (alcohol), equivalent to 18 ml beer or 7 ml wine per 25 mg dose. Patients receiving the higher dose of 175 mg of Torisel for the initial treatment of mantle cell lymphoma may receive a dose of ethanol equivalent to up to 122 ml beer or 49 ml wine per dose. It is harmful if you are suffering from alcoholism, and it is to be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease or epilepsy.
The amount of alcohol in this medicine is not likely to have an effect in adults and adolescents, and its effects in children are not likely to be noticeable. It may have some effects in babies and young children, for example feeling sleepy. If you are addicted to alcohol, talk to your doctor or pharmacist before taking this medicine.
The amount of alcohol in this medicine may alter the effects of other medicines. Talk to your doctor or pharmacist if you are taking other medicines.
The amount of alcohol in this medicine may impair your ability to drive or alter the effects of other medicines (see sections Warning and precautions and Driving and using machines ).
Torisel contains propylene glycol
Torisel contains 503.3 mg propylene glycol in each 25 mg dose which is equivalent to 201.33 mg/ml diluted product. If your child is less than 5 years old, talk to your doctor or pharmacist before giving them this medicine, in particular if they are being given other medicines that contain propylene glycol or alcohol. If you are pregnant or breast feeding, or if you suffer from liver or kidney disease, do not take this medicine unless recommended by your doctor. Your doctor may carry out extra checks while you are taking this medicine.
Torisel will always be prepared and given to you by a doctor or another healthcare professional as an intravenous infusion (into your vein).
You should receive an injection of antihistamine (to try to prevent allergic reaction to Torisel) directly into your vein approximately 30 minutes before your dose of Torisel.
The Torisel concentrate must first be diluted with 1.8 ml of the supplied solvent to achieve a concentration of 10 mg/ml before administration in sodium chloride 9 mg/ml (0.9%) solution for injection (see dilution instructions at the end of the package leaflet).
For renal cancer, the recommended dose is 25 mg infused (as a drip) over a 30 to 60 minute period once weekly.
For mantle cell lymphoma, the recommended dose is 175 mg infused (as a drip) over a 30 to 60 minute period once weekly for 3 weeks followed by single weekly doses of 75 mg infused (as a drip) over a 30 to 60 minute period.
Treatment with Torisel should continue until you are no longer benefiting from therapy or until unacceptable side effects occur.
As this medicine is prepared and given by a healthcare professional, it is unlikely you will be given too much or that you will miss a dose.
If you are concerned about this, tell your doctor immediately.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Side effects may be more pronounced with the higher dose of 175 mg per week during initial treatment for mantle cell lymphoma.
The most important side effects you may experience during the treatment with Torisel are listed below. If you experience any of them, seek medical advice immediately.
Allergic reactions
You should tell your doctor or nurse immediately if you have symptoms of angioedema, such as swollen face, tongue or pharynx, and difficulty in breathing.
If you experience any of these during the administration of Torisel, the doctor or nurse will stop the infusion.
Bleeding in the brain
You should seek medical advice immediately if you feel confused, unusually tired, have difficulty in speaking or in swallowing and your pupils have different sizes. These symptoms might be caused by a bleeding in the brain.
Intestinal puncture, tear or holes
You should seek medical advice immediately if you have acute abdominal pain, high fever, nausea and vomiting, or blood in the stools. These symptoms might be caused by a perforation in your gut.
Kidney failure
You should seek medical advice immediately if you suffer from general swelling, shortness of breath, tiredness. These symptoms might be caused by a sudden decrease of kidney function.
Embolism in the lung
You should seek medical advice immediately if you experience shortness of breath, chest pain, coughing up blood, fast heartbeat, nausea, fainting, sweating, wheezing, and clammy or bluish skin. These symptoms might be caused by a blood clot in your lung.
You should also tell your doctor straight away
if you have cough, chest pain, difficulties in breathing. Your doctor may prescribe you an x-ray examination of your chest.
if the number of white cells in your blood has decreased. This may increase the risk of getting fever and infections.
if the number of platelet (a type of blood cell that helps to clot blood) has decreased. This may increase the risk of bleeding in your body.
if your blood levels of cholesterol and triglycerides have increased.
if you experience any excessive thirst or increased frequency and quantity of urination. Your doctor may prescribe you insulin and/or oral antidiabetic agent therapy.
if you have recently undertaken a surgery. Your doctor may delay the administration of Torisel until the wound is fully recovered as this medicine could interfere with the healing processes of pre-existing wounds.
Other side effects with Torisel may include
Very common side effects (may affect more than 1 in 10 people)
General feeling of weakness, chills, swelling due to fluid retention, pain (including abdominal, back, chest and joint pain), feeling sick to the stomach (nausea and vomiting), diarrhoea, constipation , headache, fever, sores and inflammation in the mouth and/or the digestive tract, cough, pneumonia, nose bleed, rash, itching, dry skin, decreased appetite, shortness of breath, low levels of potassium in the blood (which may cause muscle weakness), low red blood cell count, decreased number of a type of white blood cells which is associated with an increased risk of infection, high blood sugar, high cholesterol, high triglycerides abscess, infections ( including eye infection, flu, viral infections, bronchitis), abnormal kidney function (including kidney failure), blood tests that show changes in the way the kidney is working, change in the sense of taste, difficulty falling asleep, low number of platelets which may cause bleeding and bruising.
Common side effects (may affect up to 1 in 10 people)
Runny nose, gum redness and swelling, mouth pain (including sores inside the mouth), stomach bloating, sore throat, high blood pressure, pink eye including watery eye disorder, taste loss, redness and swelling of the follicles in the skin, allergic reactions, severe scaling of the skin, increased blood clotting (including thrombosis of the veins), low levels of calcium in the blood, low levels of phosphates in the blood, upper respiratory infections, inflammation of the lung, fluid in the chest cavity, infection in the blood, dehydration, agitation, depression, numbness and tingling of the skin, dizziness, sleepiness, bleeding (from the lips, mouth, stomach or intestines), inflammation of the lining of the stomach, trouble with swallowing, skin bleeding (bruising), small pin-point haemorrage, nail disorder, acne, yeast infection, fungal infection, urinary tract infections, cystitis, blood tests that show changes in the way the liver is working, high blood fats other than triglycerides, diabetes, muscle pain.
Uncommon side effects (may affect up to 1 in 100 people)
Pericardial effusion (fluid around the heart that may require drainage and can affect the pumping of blood).
Bleeding into the brain in patients with brain tumours or who are on blood thinners, eye bleeding.
Embolism of the lung, perforation of the gut, problems with wound healing after surgery, inflammation and swelling of the voice box.
Rare side effects (may affect up to 1 in 1,000 people)
Lung infection caused by Pneumocystis jiroveci (Pneumocystis jiroveci pneumonia).
Side effects for which frequency is not known (cannot be estimated from available data)
Swelling of the face, lips, tongue, and throat, possibly causing difficulty breathing.
Serious reactions of the skin and/or mucous membranes which may include painful blisters and fever (Stevens-Johnson syndrome).
Unexplained muscle pain, tenderness or weakness which could indicate muscle damage (rhabdomyolysis)
Reporting of side effects If you get any side effect, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date, which is stated on the vial label and carton. The expiry date refers to the last day of that month.
Store in a refrigerator (2 C - 8 C)
Do not freeze.
Keep the vials in the outer carton in order to protect from light.
After first dilution of the concentrate with 1.8 ml of the supplied solvent, the mixture may be stored for up to 24 hours below 25 C and protected from light prior to further dilution.
After further dilution of the concentrate-solvent mixture with sodium chloride 9 mg/ml (0.9%) solution for injection, the solution may be stored for up to 6 hours below 25 C and protected from light.
Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Torisel contains
Each vial of concentrate contains 30 mg of temsirolimus.
After first dilution of the concentrate with 1.8 ml of the supplied solvent, the concentration of temsirolimus is 10 mg/ml.
What Torisel looks like and contents of the pack
Torisel is a concentrate and solvent for solution for infusion. The concentrate is a clear, colourless to light-yellow solution. The solvent is a clear to slightly turbid, light-yellow to yellow solution. The solutions are essentially free from visible particulates.
Each pack of Torisel contains one glass vial of 1.2 ml of concentrate and one glass vial of 2.2 ml of solvent.
Marketing Authorisation Holder Pfizer Europe MA EEIG Boulevard de la Plaine 1050 Bruxelles Belgium
Manufacturer Wyeth Lederle S.r.l. Via Franco Gorgone Zona Industriale 95100 Catania Italy
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien
Pfizer S.A./ N.V.
T l/Tel: +32 (0)2 554 62 Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel. +3705 2514
,
.: +359 2 970 4Luxembourg/Luxemburg
Pfizer S.A./ N.V.
T l/Tel: +32 (0)2 554 62 esk republika
Pfizer, spol. s r.o. Tel: +420 283 004 Magyarorsz g
Pfizer Kft.
Tel.: +36 1 488 3Danmark
Pfizer ApS
Tlf: +45 44 201 Malta
Vivian Corporation Ltd.
Tel: +35621 344Deutschland
Pfizer Pharma GmbH Tel: +49 (0)30 550055-51Nederland
Pfizer bv Tel: +31 (0)10 406 43 Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7Norge
Pfizer AS
Tlf: +47 67 52 61
PFIZER A.E. T : +30 210 67 85 sterreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0 Espa a
Pfizer, S.L.
Tel: +34 91 490 99 Polska
Pfizer Polska Sp. z o.o.,
Tel: +48 22 335 61 France
Pfizer T l: +33 (0)1 58 07 34 Portugal Laborat rios Pfizer, Lda. Tel: +351 21 423 5Hrvatska Pfizer Croatia d.o.o. Tel: + 385 1 3908 Rom nia Pfizer Romania S.R.L
Tel: +40 (0) 21 207 28 Ireland
Pfizer Healthcare Ireland Tel: +1800 633 363 (toll free) Tel: +44 (0)1304 616Slovenija Pfizer Luxembourg SARL, Pfizer, podru nica za svetovanje s podro ja farmacevtske dejavnosti, Ljubljana
Tel: +386 (0)1 52 11 sland
Icepharma hf. S mi: +354 540 8Slovensk republika Pfizer Luxembourg SARL, organiza n zlo ka Tel: +421 2 3355 5Italia
Pfizer S.r.l Tel: +39 06 33 18 Suomi/Finland
Pfizer Oy
Puh/Tel: +358 (0)9 430
PFIZER . . (CYPRUS BRANCH) T : +357 22 817Sverige
Pfizer AB Tel: +46 (0)8 550 520 Latvija Pfizer Luxembourg SARL fili le Latvij
Tel. +371 67035United Kingdom (Northern Ireland) Pfizer Limited Tel: +44 (0)1304 616This leaflet was last revised in <{MM/YYYY}>
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-4e8e0c5f72dbc27f3ff2eb4a522fe300
Resource Composition:
Generated Narrative: Composition composition-en-4e8e0c5f72dbc27f3ff2eb4a522fe300
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/07/424/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - torisel
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp4e8e0c5f72dbc27f3ff2eb4a522fe300
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp4e8e0c5f72dbc27f3ff2eb4a522fe300
identifier:
http://ema.europa.eu/identifier
/EU/1/07/424/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Torisel 30 mg concentrate and solvent for solution for infusion
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en